SugoSure Beta Test
The SugoSure Beta Test was run from November 2019 to April 2020 in collaboration with 15 patients, 2 health coaches and 6 physicians (2 specialists and 4 GPs from a large corporate medical group).
This was the first time a close-to-market-ready version of SugoSure was used with full involvement from physicians and health coach support. Its objectives were to test user reaction, provide initial data about outcomes improvement and to inform further product refinement prior to commercial launch.
The Beta Test has shown promising results in SugoSure's target patient group (HbA1c > 7.0% at start). These patients showed a major improvement in glycaemic control over only 3 months with a 14.9% reduction in average Pre-Meal Blood Glucose and a 0.8 point reduction in HbA1c
Outcomes & Patient Segmentation
Although a criterion for admission to the Beta Test was an HbA1c reading >7.0% in the prior 3 months, several patients had improved their control just before the Beta Test started so that their HbA1c at Beta Test start was actually at 7.0% or less.
7 out of the 15 patients analysed fell into this start HbA1c 7.0% or less group whereas the other 8 patients started the Beta Test with an HbA1c >7.0%. While many of the start HbA1c 7.0% or less group still showed improvements, these were smaller than in the other group.
This was not surprising since the need for change was less pressing in the HbA1c<7.0% group, which was already generally well-controlled with good diets and stable medication. Motivation in this group seemed lower and many of this group decided not to continue with SugoSure after 3 months.
In contrast, several of the 8 patients who started the Beta Test with HbA1c >7.0% had somewhat poor control with BG readings largely out of range at the start. Many in this group placed concerted focus on lifestyle changes with support from health coaches and remote monitoring (in some cases also remote intervention through medication dosage changes) by their doctor.
Use of SugoSure over the first 3 months clearly paid off for patients with HbA1c >7.0% with some impressive drops in HbA1c and major lifestyle improvements achieved
The 2 patients showing the greatest improvement in HbA1c reduced this by 2.5 and 1.4 points. In both cases the patients achieved their target 5kg weight reduction and one of these patients increased activity levels up to 15,000 steps per day!
Patient Questionnaire Feedback
- 11/15 patients agreed or strongly agreed that they enjoyed using the app and found it easy to use while 13/15 agreed or strongly agreed that they found it useful
- 12/15 patients agreed or strongly agreed that they felt more closely monitored by their doctor using SugoSure, and that this enabled their doctor to provide better care - also assisted by inputs from their health coach
- Compliance levels were better than expected, reflecting the finding that all patients claimed to be willing to make the effort to log food and blood glucose levels in line with protocols to better manage their diabetes
- Patient satisfaction with their diabetes management reached 100% after 3 months use of SugoSure: only 9/15 patients were either somewhat satisfied or very satisfied at the start of the Beta Test compared to 15/15 (all) patients after 3 months.
The Beta Test has shown strong support for the value of SugoSure in improving outcomes for patients with suboptimal or poor glycaemic control, albeit in a limited number of patients to date. Several of the Beta Test patients have continued to use SugoSure, some now in their 9th month of use (as at end August 2020). Almost all have sustained improvements made in the first 3 months and some have continued to step up their activity, learn more about their diet and lose weight.